Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Outpatients

• Men and women age 18 years of age and older

• Women of childbearing potential participating in the study must have a negative serum pregnancy test result at screening and use a medically acceptable form of contraception

Exclusion Criteria:

• Treatment with DVS-233 SR at any time in the past

• Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1

• Known hypersensitivity to venlafaxine (IR or ER)

• Significant risk of suicide based on clinical judgment, including common